{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:34:22Z","timestamp":1791135262118,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T00:00:00Z","timestamp":1421280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s13277-015-3067-1","type":"journal-article","created":{"date-parts":[[2015,1,13]],"date-time":"2015-01-13T18:14:37Z","timestamp":1421172877000},"page":"4287-4292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Adiponectin inhibits VEGF-A in prostate cancer cells"],"prefix":"10.1007","volume":"36","author":[{"given":"Qiruo","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,15]]},"reference":[{"key":"3067_CR1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nrclinonc.2013.14","volume":"10","author":"PJ Saylor","year":"2013","unstructured":"Saylor PJ. Prostate cancer: the androgen receptor remains front and centre. Nat Rev Clin Oncol. 2013;10:126\u20138.","journal-title":"Nat Rev Clin Oncol"},{"key":"3067_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/PPO.0b013e318281197e","volume":"19","author":"A Alva","year":"2013","unstructured":"Alva A, Hussain M. The changing natural history of metastatic prostate cancer. Cancer J. 2013;19:19\u201324.","journal-title":"Cancer J"},{"key":"3067_CR3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1078-0432.CCR-12-1452","volume":"19","author":"H Beltran","year":"2013","unstructured":"Beltran H, Rubin MA. New strategies in prostate cancer: translating genomics into the clinic. Clin Cancer Res. 2013;19:517\u201323.","journal-title":"Clin Cancer Res"},{"key":"3067_CR4","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1038\/onc.2012.541","volume":"32","author":"L Xin","year":"2013","unstructured":"Xin L. Cells of origin for cancer: an updated view from prostate cancer. Oncogene. 2013;32:3655\u201363.","journal-title":"Oncogene"},{"key":"3067_CR5","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1007\/s13277-014-1818-z","volume":"35","author":"S Huang","year":"2014","unstructured":"Huang S, Liao Q, Li L, Xin D. PTTG1 inhibits SMAD3 in prostate cancer cells to promote their proliferation. Tumour Biol. 2014;35:6265\u201370.","journal-title":"Tumour Biol"},{"key":"3067_CR6","doi-asserted-by":"crossref","first-page":"8537","DOI":"10.1007\/s13277-014-2368-0","volume":"35","author":"Q Xia","year":"2014","unstructured":"Xia Q, Li C, Bian P, Wang J, Dong S. Targeting SMAD3 for inhibiting prostate cancer metastasis. Tumour Biol. 2014;35:8537\u201341.","journal-title":"Tumour Biol"},{"key":"3067_CR7","doi-asserted-by":"crossref","unstructured":"Zhang Q, Hong B, Wu S, Niu T. Inhibition of prostatic cancer growth by ginsenoside Rh2. Tumour Biol. 2014.","DOI":"10.1007\/s13277-014-2845-5"},{"key":"3067_CR8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1517\/14728222.2012.668887","volume":"16","author":"ES Antonarakis","year":"2012","unstructured":"Antonarakis ES, Carducci MA. Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets. 2012;16:365\u201376.","journal-title":"Expert Opin Ther Targets"},{"key":"3067_CR9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1517\/14656560903451716","volume":"11","author":"PG Kluetz","year":"2010","unstructured":"Kluetz PG, Figg WD, Dahut WL. Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother. 2010;11:233\u201347.","journal-title":"Expert Opin Pharmacother"},{"key":"3067_CR10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/1874467210902020161","volume":"2","author":"JB Aragon-Ching","year":"2009","unstructured":"Aragon-Ching JB, Dahut WL. VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol. 2009;2:161\u20138.","journal-title":"Curr Mol Pharmacol"},{"key":"3067_CR11","first-page":"3669","volume":"14","author":"NB Delongchamps","year":"2007","unstructured":"Delongchamps NB, Peyromaure M. The role of vascular endothelial growth factor in kidney and prostate cancer. Can J Urol. 2007;14:3669\u201377.","journal-title":"Can J Urol"},{"key":"3067_CR12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.urology.2006.03.010","volume":"68","author":"NB Delongchamps","year":"2006","unstructured":"Delongchamps NB, Peyromaure M, Dinh-Xuan AT. Role of vascular endothelial growth factor in prostate cancer. Urology. 2006;68:244\u20138.","journal-title":"Urology"},{"key":"3067_CR13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/ATVBAHA.108.179663","volume":"29","author":"N Ferrara","year":"2009","unstructured":"Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009;29:789\u201391.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3067_CR14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bcmd.2006.12.003","volume":"38","author":"ZK Otrock","year":"2007","unstructured":"Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis. 2007;38:258\u201368.","journal-title":"Blood Cells Mol Dis"},{"key":"3067_CR15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/biof.46","volume":"35","author":"BJ Nieves","year":"2009","unstructured":"Nieves BJ, D'Amore PA, Bryan BA. The function of vascular endothelial growth factor. Biofactors. 2009;35:332\u20137.","journal-title":"Biofactors"},{"key":"3067_CR16","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00125-014-3179-y","volume":"57","author":"X Xiao","year":"2014","unstructured":"Xiao X, Prasadan K, Guo P, El-Gohary Y, Fischbach S, Wiersch J, et al. Pancreatic duct cells as a source of VEGF in mice. Diabetologia. 2014;57:991\u20131000.","journal-title":"Diabetologia"},{"key":"3067_CR17","doi-asserted-by":"crossref","first-page":"8636","DOI":"10.1074\/jbc.M112.422949","volume":"288","author":"X Xiao","year":"2013","unstructured":"Xiao X, Guo P, Chen Z, El-Gohary Y, Wiersch J, Gaffar I, et al. Hypoglycemia reduces vascular endothelial growth factor a production by pancreatic beta cells as a regulator of beta cell mass. J Biol Chem. 2013;288:8636\u201346.","journal-title":"J Biol Chem"},{"key":"3067_CR18","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.eururo.2012.11.013","volume":"63","author":"EH Allott","year":"2013","unstructured":"Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63:800\u20139.","journal-title":"Eur Urol"},{"key":"3067_CR19","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.2174\/092986712803833137","volume":"19","author":"S Perrier","year":"2012","unstructured":"Perrier S, Jarde T. Adiponectin, an anti-carcinogenic hormone? A systematic review on breast, colorectal, liver and prostate cancer. Curr Med Chem. 2012;19:5501\u201312.","journal-title":"Curr Med Chem"},{"key":"3067_CR20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.eururo.2007.04.069","volume":"52","author":"WC Buschemeyer 3rd","year":"2007","unstructured":"Buschemeyer 3rd WC, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol. 2007;52:331\u201343.","journal-title":"Eur Urol"},{"key":"3067_CR21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.eururo.2007.03.054","volume":"52","author":"T Mistry","year":"2007","unstructured":"Mistry T, Digby JE, Desai KM, Randeva HS. Obesity and prostate cancer: a role for adipokines. Eur Urol. 2007;52:46\u201353.","journal-title":"Eur Urol"},{"issue":"Suppl 2","key":"3067_CR22","first-page":"11","volume":"13","author":"RL O'Malley","year":"2006","unstructured":"O'Malley RL, Taneja SS. Obesity and prostate cancer. Can J Urol. 2006;13 Suppl 2:11\u20137.","journal-title":"Can J Urol"},{"key":"3067_CR23","first-page":"737","volume":"28","author":"J Baillargeon","year":"2006","unstructured":"Baillargeon J, Rose DP. Obesity, adipokines, and prostate cancer (review). Int J Oncol. 2006;28:737\u201345.","journal-title":"Int J Oncol"},{"key":"3067_CR24","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature01705","volume":"423","author":"T Yamauchi","year":"2003","unstructured":"Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762\u20139.","journal-title":"Nature"},{"key":"3067_CR25","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1210\/jc.2004-0518","volume":"89","author":"BJ Goldstein","year":"2004","unstructured":"Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004;89:2563\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"3067_CR26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1677\/ERC-06-0091","volume":"14","author":"D Barb","year":"2007","unstructured":"Barb D, Neuwirth A, Mantzoros CS, Balk SP. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer. 2007;14:995\u20131005.","journal-title":"Endocr Relat Cancer"},{"key":"3067_CR27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","volume":"115","author":"K Inoki","year":"2003","unstructured":"Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577\u201390.","journal-title":"Cell"},{"key":"3067_CR28","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","volume":"4","author":"K Inoki","year":"2002","unstructured":"Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648\u201357.","journal-title":"Nat Cell Biol"},{"key":"3067_CR29","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1111\/j.1600-6143.2008.02391.x","volume":"8","author":"EK Geissler","year":"2008","unstructured":"Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer and transplantation. Am J Transplant. 2008;8:2212\u20138.","journal-title":"Am J Transplant"},{"key":"3067_CR30","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.4161\/cc.6.24.5085","volume":"6","author":"DF Lee","year":"2007","unstructured":"Lee DF, Hung MC. All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle. 2007;6:3011\u20134.","journal-title":"Cell Cycle"},{"key":"3067_CR31","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1158\/1078-0432.CCR-12-0930","volume":"19","author":"MN Vansaun","year":"2013","unstructured":"Vansaun MN. Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res. 2013;19:1926\u201332.","journal-title":"Clin Cancer Res"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3067-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-015-3067-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3067-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3067-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T13:25:02Z","timestamp":1566221102000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-015-3067-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,15]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["3067"],"URL":"https:\/\/doi.org\/10.1007\/s13277-015-3067-1","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,15]]}}}